A5051410188- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- PI3K/AKT/mTOR signaling in cancer
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Chronic Lymphocytic Leukemia Research
- CRISPR and Genetic Engineering
- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Radiopharmaceutical Chemistry and Applications
- DNA Repair Mechanisms
- Genomics and Chromatin Dynamics
- Ovarian cancer diagnosis and treatment
- Click Chemistry and Applications
- interferon and immune responses
- Eating Disorders and Behaviors
- Genomics and Rare Diseases
- Animal Virus Infections Studies
- Bioinformatics and Genomic Networks
- Herpesvirus Infections and Treatments
- Obesity and Health Practices
IPO Porto
2025
University of Milano-Bicocca
2024
Peter MacCallum Cancer Centre
2016-2022
King's College London
2020
Institut de Génétique Humaine
2013-2018
Walter and Eliza Hall Institute of Medical Research
2017
The University of Melbourne
2017
Centre National de la Recherche Scientifique
2012
Background Understanding the cancer genome is seen as a key step in improving outcomes for patients. Genomic assays are emerging possible avenue to personalised medicine breast cancer. However, evolution of during natural history largely unknown, profile disease at death. We sought study detail these aspects advanced cancers that have resulted lethal disease. Methods and Findings Three patients with oestrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative...
Abstract Venetoclax, a potent and selective BCL2 inhibitor, synergizes with endocrine therapy in preclinical models of ER-positive breast cancer. Using phase Ib 3 + dose-escalation expansion study design, 33 patients ER BCL2-positive metastatic disease (mean prior regimens, 2; range, 0–8) were treated daily tamoxifen (20 mg) venetoclax (200–800 mg). Apart from uncomplicated “on-target” lymphopenia, no dose-limiting toxicities or high-grade adverse events observed the escalation (15...
In the neoadjuvant treatment (NAT) setting, dual HER2-targeted therapy is associated with increased pathologic complete response (pCR) rates compared each alone. Biomarkers allowing to predict during NAT are needed. We aim evaluate whether circulating tumor DNA (ctDNA) anti-HER2-targeted therapy.Plasma collected before NAT, at week 2, and surgery from patients enrolled in NeoALTTO trial was assessed using digital PCR for PIK3CA TP53 mutation detection.A total of 69 455 (15.2%) had a and/or...
Circulating tumor DNA (ctDNA) allows noninvasive disease monitoring across a range of malignancies. In metastatic melanoma, the extent to which ctDNA reflects changes in metabolic burden assessed by 18F-labeled fluorodeoxyglucose positron emission tomography (FDG-PET) is unknown. We role analysis combination with FDG-PET monitor and genomic heterogeneity throughout treatment.We performed comprehensive serial 52 patients who received systemic therapy for melanoma. Next-generation sequencing...
Several novel therapeutics are poised to change the natural history of chronic lymphocytic leukaemia (CLL) and increasing use these therapies has highlighted limitations traditional disease monitoring methods. Here we demonstrate that circulating tumour DNA (ctDNA) is readily detectable in patients with CLL. Importantly, ctDNA does not simply mirror genomic information contained within malignant lymphocytes but instead parallels changes across different compartments following treatment...
Abstract There is limited knowledge on the benefit of α-subunit–specific PI3K inhibitor alpelisib in later lines therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study monotherapy patients with pathway mutant ER+HER2− TNBC. In intention-to-treat ER+ cohort, overall response rate was 30% clinical 36%. A decline circulating tumor DNA (ctDNA) levels from baseline to week 8 while significantly associated...
Introduction A combination of ipilimumab/nivolumab has demonstrated a median overall survival (mOS) 71.9 months in advanced melanoma, establishing it as the standard first-line (1L) therapy. However, approval this by Portuguese Regulatory Authority occurred 76 after its European Authority, leaving tyrosine kinase inhibitors only 1L option available for BRAF-mutated melanoma population. Our study aims to evaluate real-world data from patients with and assess potential prognostic impact...
Abstract Background To evaluate the association between weight misperception and psychological symptoms in Determinants of young Adults Social well-being Health (DASH) longitudinal study. Methods A sample 3227 adolescents, 49 secondary schools London, aged 11–16 years participated 2002/2003 were followed up 2005/2006. sub-sample ( N = 595) was again at ages 21–23 2012/2013. An index derived from perception measured weight. Psychological well- being using Strengths Difficulties Questionnaire...
Background Metastatic breast cancer (mBC) is a heterogenous disease with increasing availability of targeted therapies as well emerging genomic markers therapeutic resistance, necessitating timely and accurate molecular characterization disease. As minimally invasive test, analysis circulating tumour DNA (ctDNA) positioned for real-time profiling to guide treatment decisions. Here, we report the results prospective testing program established assess feasibility ctDNA clinical management mBC...
<p>Supplementary Tables S1-5</p>
<p>Supplementary Tables S1-5</p>
<div>Abstract<p>There is limited knowledge on the benefit of α-subunit–specific PI3K inhibitor alpelisib in later lines therapy for advanced estrogen receptor–positive (ER<sup>+</sup>) HER2<sup>−</sup> and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study monotherapy patients with pathway mutant ER<sup>+</sup>HER2<sup>−</sup> TNBC. In intention-to-treat ER<sup>+</sup> cohort, overall...
<div>Abstract<p>There is limited knowledge on the benefit of α-subunit–specific PI3K inhibitor alpelisib in later lines therapy for advanced estrogen receptor–positive (ER<sup>+</sup>) HER2<sup>−</sup> and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study monotherapy patients with pathway mutant ER<sup>+</sup>HER2<sup>−</sup> TNBC. In intention-to-treat ER<sup>+</sup> cohort, overall...
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
<p>Supplementary Table S8</p>
<p>Supplementary Methods</p>